Clozapine is associated with significant weight gain and metabolic disturbances. This multicentre, randomized study comprised a double-blind, placebo-controlled treatment phase of 16 wk, and an open-label extension phase of 12 wk. Outpatients who met DSM-IV-TR criteria for schizophrenia, who were not optimally controlled while on stable dosage of clozapine for o3 months and had experienced weight gain of o2.5 kg while taking clozapine, were randomized (n=207) to aripiprazole at 5-15 mg/d or placebo, in addition to a stable dose of clozapine. The primary endpoint was mean change from baseline in body weight at week 16 (last observation carried forward). Secondary endpoints included clinical efficacy, body mass index (BMI) and waist circumference. A statistically significant difference in weight loss was reported for aripiprazole vs. placebo (x2.53 kg vs. x0.38 kg, respectively, difference=x2.15 kg, p<0.001). Aripiprazole-treated patients also showed BMI (median reduction 0.8 kg/m 2 ) and waist circumference reduction (median reduction 2.0 cm) vs. placebo (no change in either parameter, p<0.001 and p=0.001, respectively). Aripiprazole-treated patients had significantly greater reductions in total and low-density lipoprotein (LDL) cholesterol. There were no significant differences in Positive and Negative Syndrome Scale total score changes between groups but Clinical Global Impression Improvement and Investigator's Assessment Questionnaire scores favoured aripiprazole over placebo. Safety and tolerability were generally comparable between groups. Combining aripiprazole and clozapine resulted in significant weight, BMI and fasting cholesterol benefits to patients suboptimally treated with clozapine. Improvements may reduce metabolic risk factors associated with clozapine treatment.
Introduction
Clozapine is the treatment of choice for severely ill patients with schizophrenia who are refractory to conventional treatment (Fleischhacker, 1999 ; Kane et al. 2003) , but the drug is associated with significant weight gain and metabolic disturbances (for review, see Newcomer, 2005) . In addition to increasing the risk of cardiovascular disease and diabetes (American Diabetes Association, APA, 2004) , these effects can severely impair patients ' quality of life (Allison et al. 2003) and may represent a barrier to medication adherence (Weiden et al. 2000) . Aripiprazole, a newgeneration antipsychotic, has a lower risk of metabolic side-effects than second-generation drugs (Brixner et al. 2006 ; Fleischhacker et al. 2009 ; Newcomer, 2005) . It is a partial agonist at dopamine D 2 receptors and 5-HT 1A receptors, and an antagonist at 5-HT 2A and 5-HT 2C receptors (Burris et al. 2002 ; Fleischhacker, 2005 ; Jordan et al. 2002 ; Keck & McElroy, 2003 ; Shapiro et al. 2003) . Small-scale studies have indicated that the addition of aripiprazole (with low risk of weight gain) to clozapine therapy (high risk of weight gain) may result in improvements in schizophrenia symptoms as well as body weight and metabolic variables (Englisch & Zink, 2008) . These preliminary findings constituted the clinical rationale to further explore this approach. This randomized, double-blind trial was conducted to provide a robust evaluation of the effect of adjunctive therapy of aripiprazole+clozapine vs. clozapine monotherapy on body weight and clinical efficacy in patients with schizophrenia.
Method

Study design
The main study was a 16-wk, multicentre, randomized, double-blind, placebo-controlled trial. Participants initially entered a 2-to 35-d pre-treatment screening phase in which eligibility for the study was assessed. Eligible patients then entered a 16-wk double-blind phase in which their clozapine dose was maintained and they were additionally randomized to treatment with either aripiprazole or placebo, according to a computer-generated randomization schedule. Randomization was achieved by a call-in interactive voice response system, from which a patient identification number was assigned. Treatment assignments were governed by a fixed block (block size=4) randomization schedule. Within each centre, approximately equal numbers of patients were assigned to each treatment group.
During the double-blind phase, patients initially received 5 mg/d aripiprazole for 2 wk, after which investigators had the option of increasing the dose to 10 mg/d or remaining at 5 mg/d for the following 2 wk. After 4 wk, the dose of double-blind aripiprazole was flexible between 5 and 15 mg/d and could be adjusted in 5-mg increments at the scheduled visits. The clozapine dose was maintained throughout the double-blind phase. Patients requiring an adjustment of the clozapine dose were withdrawn from the study. Antipsychotic agents other than aripiprazole and clozapine were prohibited, as were investigational agents and medications or nutritional supplements for the purpose of weight loss or weight gain, as well as drugs known to have a substantial potential to depress bone marrow function. Benzodiazepines and anticholinergics were allowed at any time, if necessary, along with sleep aids if the patient was not already taking a benzodiazepine for insomnia. Prescribed antidepressants and mood stabilizers were allowed at a stable dose during the study if the patient had been taking these medications before study entry. Propranolol (60 mg/d) was allowed for the treatment of akathisia.
Patients completing the double-blind phase and considered eligible by the investigator could enter an open-label extension phase for an additional 12 wk. All patients received 5-15 mg/d aripiprazole and the clozapine dose could be decreased or increased, providing the dose did not exceed that taken in the double-blind phase.
The study was performed at 55 centres in 10 European countries and South Africa. It was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki and within relevant local Ministry of Health regulations. The protocol and informed consent forms were approved by local Institutional Review Boards or Ethics Committees at all participating centres. Before participation in the study, informed consent was obtained from all patients or, where consent could not be given by the patient, their legally acceptable representative.
Patients
Patients were aged 18-65 yr with a diagnosis of schizophrenia according to DSM-IV-TR criteria (APA, 2000) . At the time of enrolment, all patients were being treated on an outpatient basis and had been receiving a stable dose of clozapine (200-900 mg/d) for at least 3 months. Included patients were not optimally controlled while on clozapine, and were required to have experienced o2.5 kg weight gain during clozapine treatment. Less than optimal control was defined as residual positive, negative or other symptoms, as well as safety/tolerability problems such as somnolence, weight gain, prolactin elevation, akathisia or extrapyramidal symptoms (EPS). Patients were also required to have the ability to comply with study procedures, including reporting for scheduled visits and providing information to allow assessment of efficacy, safety and quality of life.
Patients who were at risk for committing suicide (i.e. active, clinically significant suicidal ideation or a recently attempted suicide) were excluded, as were those with a diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic symptoms, or organic mental disorders. Those who met DSM-IV-TR criteria for any significant psychoactive substance use disorder within the 3 months before screening were also excluded, as well as those with a history of neuroleptic malignant syndrome, epilepsy, seizures or stroke, or a history or evidence of other medical conditions or abnormal laboratory parameters that would expose the patient to undue risk or interfere with study assessments. Women who were pregnant or breastfeeding, or unwilling to use a suitable method of contraception were also excluded.
Assessments and endpoints
The primary objective of the study was to assess mean change from baseline to week 16 in body weight in patients receiving add-on placebo to clozapine monotherapy compared to those receiving adjunctive aripiprazole. Body weight was recorded to the nearest 0.1 kg as the average of two measurements at baseline and at weeks 1-4, 6, 8, 12 and 16 or the end of treatment. For patients entering the open-label extension phase, body weight was measured at 4-wk intervals.
Secondary endpoints included efficacy evaluated by mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score (Kay et al. 1987) , Positive, Negative, General Psychopathology, Cognitive, and Excitement subscale scores, and the mean Clinical Global Impression Improvement (CGI-I) Scale score (Guy, 1976) . Other outcome measures included the mean Investigator Assessment Questionnaire (IAQ) total score, an instrument measuring relative effectiveness (efficacy, safety, and tolerability) of antipsychotic medications in patients with schizophrenia or schizoaffective disorder (Tandon et al. 2005 ) and the mean change from baseline in Global Assessment of Functioning (GAF) Scale score (APA, 2000) . Patientreported outcomes were evaluated using the GEOPTE [Grupo Españ ol para la Optimizació n del Tratamiento de la Esquizofrenia (Social Cognition in Schizophrenia Scale)] summary scores and index which measures social cognition in schizophrenia (Sanjuan et al. 2003) , mean change from baseline in Epworth Sleepiness Scale (ESS) total score which measures alertness (Johns, 1991) , Fatigue Syndrome Inventory (FSI) Disruption Index (Hann et al. 1998) which is designed to assess the severity, frequency, and daily pattern of fatigue as well as its perceived interference with quality of life, and patient Subjective Well Being under Neuroleptics (SWN -short form) total score and subscores which evaluate subjective well-being under neuroleptics (Naber, 1995) . Safety and tolerability were evaluated by a clinician at all time-points by reports of extrapyramidal symptoms using the Simpson-Angus Scale (SAS) total score (Simpson & Angus, 1970) , adverse events/serious adverse event (AE/SAE) reports, fasting metabolic laboratory parameters, clinically relevant changes in electrocardiograms (ECGs), vital signs, waist circumference and body mass index (BMI).
Statistical analysis
The primary outcome measure was the mean change in body weight from baseline to week 16 using last observation carried forward (LOCF) data. The planned sample size of 184 evaluable patients was designed to yield 90 % power to detect a difference of 2.5 kg in the mean change from baseline in weight at week 16 (LOCF) between aripiprazole and placebo. This calculation assumed a common standard deviation of 5.2. Allowing for withdrawals, it was expected that 200 patients would need to be randomized to have 92 evaluable patients in each treatment group. All analyses were performed using SAS statistical software, version 8.2 or higher (SAS Institute Inc., USA). All inferential analyses were interpreted at the 5 % significance level without adjustment for multiplicity. p values corresponded to two-tailed tests of significance and were rounded to three decimal places.
Mean change from baseline in weight at all study weeks was compared between treatment groups using an analysis of covariance (ANCOVA) model with baseline measurement as covariate and treatment group as main effect. As general analysis strategy for continuous efficacy measurements, the mean changes were evaluated using ANCOVA model with baseline measurement as covariate, and country and treatment group as main effects. The model for the observed case (OC) dataset did not include country as main effect. Adjusted mean CGI-I scores and mean IAQ total scores were analysed using ANCOVA with baseline CGI-S as covariate and treatment group (and country if LOCF) as main effects. Median change from baseline in BMI and waist circumference were analysed using ANCOVA, including the rank of the changes from baseline as the response variable, the rank of the baseline as the covariate and treatment group as main effect. The proportion of patients with clinically relevant (o7 % from baseline) body weight loss or gain, was compared between treatment groups using the CMH General Association test, stratified by baseline BMI category (<30/o30 kg/m 2 ). The proportion of responders (with response defined as an improvement of at least 30 % from baseline in PANSS total score) was analysed using the CMH General Association test controlling, in LOCF analyses only, for country. In the open-label extension, descriptive statistics were generated for body weight and PANSS scores (total, and positive and negative subscales).
Results
Patients and treatment
In total, 230 patients were enrolled in the study, of whom 207 were randomized. Patient demographics and disease history are shown in Table 1 . There were no significant baseline differences between the treatment groups, except for a greater body weight in the adjunctive aripiprazole group. Patient disposition is shown in Fig. 1 . The mean clozapine dose before randomization was 363 mg/d in the placebo group (range 163-900 mg/d) and 384 mg/d in patients on adjunctive aripiprazole (range 200-900 mg/d). The mean daily dose of study treatment at endpoint (safety population) was 11.1 mg/d (range 5-15 mg) in the adjunctive aripiprazole group, and 12.0 mg/d equivalent in the adjunctive placebo group. The most commonly used central nervous system concomitant medications during the study were antidepressants (29.4 % and 29.6 % in the adjunctive aripiprazole and placebo groups, respectively) and anxiolytics (33.9 % and 21.4 %, respectively). Anticholinergics were used by 5.5 % and 8.2 % of patients in the adjunctive aripiprazole and placebo groups, respectively.
Metabolic parameters
At week 16 (LOCF), the mean decrease in body weight was significantly greater with adjunctive aripiprazole compared to adjunctive placebo [x2.53 kg vs. x0.38 kg, respectively, mean treatment difference of x2.15 kg, 95 % confidence interval (CI) x3.17 to x1.12, p<0.001]. The difference was statistically significant from week 6 through to endpoint (Fig. 2) . Sensitivity analyses (including pre-specified as well as post-hoc analyses) corroborated this result. Additional post-hoc analyses investigating two subgroups with baseline BMI <30 kg/m 2 or o30 kg/m 2 also confirmed the superiority of aripiprazole compared to placebo. In a post-hoc analysis, the number-neededto-treat of patients with clinically relevant weight loss (a decrease of at least 7 % from baseline) with aripiprazole was calculated as 8 (LOCF). Examination of clinically relevant weight gain (LOCF) showed no significant difference between the two study groups in the proportion of patients with clinically relevant (o7 % from baseline) weight gain at week 16 [placebo 2.0 %, aripiprazole 1.9 % ; relative risk (RR) 0.89, 95 % CI 0.13-6.11, p=0.908]. In contrast, the proportion of patients with clinically relevant weight loss was significantly higher with aripiprazole than with placebo (15.0 % vs. 3.0 %, respectively ; RR 4.97, 95 % CI 1.49-16.59, p<0.001).
At week 16 (LOCF), patients receiving adjunctive aripiprazole experienced adjusted median reductions in BMI and waist circumference of 0.8 kg/m 2 and 2.0 cm, compared with no change in the adjunctive placebo group (p<0.001, p=0.001, respectively). A similar result in the adjusted median change from baseline in BMI was observed in the OC dataset (x0.10 vs. x0.80 for placebo vs. aripiprazole, respectively, p<0.001). The differences between treatment groups in BMI were statistically significant from week 2 onward.
Most patients entered the open-label extension phase of the study, in which all patients received adjunctive aripiprazole (Fig. 1) . The improvement in body weight seen during the double-blind phase was maintained during the extension phase. At week 28, the mean change in body weight from baseline was x1.88 kg in those who had initially received adjunctive placebo, and x3.26 kg in those who had received adjunctive aripiprazole throughout. Weight change from the end of the double-blind phase was greater in the previous adjunctive placebo group than in the previous adjunctive aripiprazole group (x1.74 kg vs. x0.47 kg, respectively). The proportions of patients with clinically relevant weight loss from baseline were 13 % and 21 %, respectively. Compared to adjunctive placebo, adjunctive aripiprazole was associated with a significant decrease in total and low-density lipoprotein (LDL) cholesterol from baseline (Table 2 ). There were no significant differences between the groups in high-density lipoprotein (HDL) cholesterol, triglycerides or fasting glucose. A similar safety profile was seen during the extension phase, with patients who initiated aripiprazole showing reduction in total cholesterol, LDL cholesterol and triglyceride values. For those patients continuing on aripiprazole from the double-blind phase, these lipid level changes were maintained.
Clinical efficacy
A total of 7 % of the placebo-treated patients and 9 % of aripiprazole-treated patients at week 16 (LOCF) reported 30 % improvement from baseline in the PANSS total score. However, the differences between treatment groups were not statistically significant (LOCF x1.1 difference, 95 % CI x3.6 to 1.4, p=0.370). Results were similar with the OC dataset. Symptom improvements were maintained during the extension phase. Patients who switched from adjunctive placebo to aripiprazole showed a mean improvement in PANSS total scores of x3.90 points between the end of the double-blind phase and week 28, compared to x1.82 points in patients previously treated with adjunctive aripiprazole. The adjusted mean CGI-I scores showed some improvement in both treatment groups at week 16 (LOCF), differing between the treatment groups in favour of aripiprazole in the adjusted mean CGI-I score at week 16 (p=0.037) ( Table 3 ). This was not corroborated by the OC dataset analysis.
The adjusted mean IAQ total scores at week 16 (LOCF) were 28.10 for the placebo group and 26.75 for the aripiprazole group, a difference favouring aripiprazole at week 16 (p=0.006) ( Table 3 ). There were no statistically significant differences in any other efficacy measures between the groups (see Table 3 for details).
Safety
During the double-blind phase, AEs were reported by 57 patients (58.2 %) in the adjunctive placebo group and 75 (68.8 %) in the adjunctive aripiprazole group. The most commonly reported AEs differentiating placebo from aripiprazole were headache (13.3 % and 9.2 %, respectively), nausea (4.1 % and 16.5 %, respectively), and anxiety (5.1 % and 13.8 %, respectively) ( Table 4) . Most AEs were mild or moderate in severity. During the double-blind phase, SAEs occurred in 10 patients in the adjunctive aripiprazole group. Three of these events (moderate sinus tachycardia, severe psychotic disorder, and severe auditory hallucinations) were considered to be possibly related to treatment. No SAEs were reported in patients receiving adjunctive placebo and no deaths were reported in either group. During the extension phase, the most common SAEs were psychiatric disorders, but most were judged by the investigator to be unrelated or probably not related to the study drug.
EPS were reported as AEs by 4.1 % of placebotreated patients and 9.2 % of aripiprazole-treated patients during the double-blind phase. Mean baseline SAS total scores were 12.58 and 12.62 in the placebo and aripiprazole groups, respectively. Both treatment groups improved from baseline to week 16 (LOCF mean change x0.46 and x0.49, on placebo and aripiprazole, respectively, p=0.892). The percentage of EPS-related AEs found during the extension phase was 3.3 % for patients treated with open-label aripiprazole. Akathisia was reported by 2.8 % of patients in the aripiprazole group during the double-blind phase, compared to 0 % of patients in the placebo group, and was the most commonly reported EPSrelated AE in both the double-blind and extension phases.
Discussion
Some new-generation antipsychotics are associated with metabolic disturbances (e.g. increased body weight, dyslipidaemia, insulin resistance) (Newcomer, 2005 ; Tschoner et al. 2007) , which can lead to increased cardiovascular burden and mortality Wilson et al. 1998) . Previous trials have shown aripiprazole to have a favourable metabolic profile (Brixner et al. 2006 ; Newcomer, 2005) , with improvement in body weight and metabolic parameters (Newcomer et al. 2008 ). The present study shows that similar benefits in physical health occur in patients receiving aripiprazole as an adjunct to clozapine. This multicentre, randomized, double-blind, placebocontrolled trial enrolled patients with schizophrenia diagnosed according to DSM-IV-TR criteria, although it should be noted that the diagnosis was not established using a structured diagnostic interview.
The study demonstrated that patients who are suboptimally managed with clozapine can benefit from adjunctive therapy with aripiprazole in terms of body weight, which was significantly reduced in patients taking aripiprazole and clozapine. Improvements in BMI and waist circumference were consistent with weight loss and suggested the potential metabolic superiority of combination therapy compared to clozapine monotherapy. There were also significant decreases in total and LDL cholesterol,
The benefits of adjunctive aripiprazole on body weight were maintained in the open-label extension, with additional benefits for patients who had previously received adjunctive placebo. Given the negative impact of weight gain and metabolic changes that are often associated with therapies for schizophrenia, these results are encouraging for patient health and adherence. Antipsychotic efficacy of clozapine was maintained with combination therapy and the two groups did not differ from each other with respect to most efficacy measures studied.
The results of this trial are consistent with previous studies of combination aripiprazole and clozapine therapy. Henderson et al. (2006) reported significant decreases in weight (p=0.003), BMI (p=0.004), fasting total serum cholesterol (p=0.002) and total triglycerides (p=0.04), with no significant change in PANSS total score in patients receiving clozapine who also received open-label aripiprazole for 6 wk. In another trial of 62 patients with schizophrenia and a history of treatment failure or partial response to long-term clozapine treatment, aripiprazole augmentation was associated with significant improvements in negative symptoms, together with significant reductions in triglyceride and prolactin levels (Chang et al. 2008) . Furthermore, a systematic review of the literature on adjunctive aripiprazole reported clinical improvement in psychotic symptoms and a clozapine dose reduction of 52 mg/d, as well as improved lipid metabolism and glucose levels (Englisch & Zink, 2008) .
Results from the present study show similar benefits to lipid metabolism ; however, no significant differences were noted with regard to fasting glucose or psychopathological symptom level. Small differences on the CGI-I score were not reflected in any other efficacy measure. As these measures were pre-specified as secondary outcomes, efficacy analyses were not powered to detect significant difference. Primary and secondary findings also need to be interpreted in the context of the relatively low mean dose of aripiprazole (11.1 mg/d) used in the study. This may have had an impact on the study results but is in line with label recommendations and not unusual with combination therapy. It should also be noted that monitoring of clozapine plasma levels was not required in the protocol. Patients attending wellness groups could continue to do so through the study. The advantages of aripiprazole regarding the IAQ score at week 16 are modest and may be the result of weight loss as well as BMI and waist circumference reductions.
However, these advantages, must be weighted against the impact of additional side-effects, including anxiety, nausea, vomiting and akathisia. Nausea, in theory at least, may contribute to weight loss and this possibility cannot be ruled out. It is likely that the figure recorded for akathisia (2.8 % incidence as treatment-emergent EPS-related AEs) is a reflection of the early effects of aripiprazole treatment, which were resolved with anxiolytic medication during the course of the study. These AEs represent important factors when considering long-term treatment of patients with schizophrenia. Additionally, although polypharmacy is common in clinical practice, it is not recommended in current guidelines, and more research is needed to identify possible drug-drug interactions.
Strengths of the present study include the design, the inclusion of a long-term follow-up phase, the size of the patient cohort, and the low drop-out rate. As with the CATIE (Lieberman et al. 2005) and EUFEST (Kahn et al. 2008 ) studies, two trials indicating a significant risk for antipsychotic-induced weight increase, the long-term follow-up of patients within the present study provides additional information on the risk/ benefit profiles of different treatment regimens. In contrast to the study by Chang et al. (2008) and the review by Englisch & Zink, (2008) we did not observe clinically meaningful PANSS improvements in either group. This may be explained by the fact that our population comprised of chronically ill patients who had been pretreated with clozapine for a mean of over 5 yr. Whether these patients had been switched to clozapine due to non-response to previous treatments or because of intolerable EPS is not known. It is possible that studying patients at an earlier stage of the illness, differentiating them by indication for clozapine and prospectively evaluating the switch to clozapine before the randomization to add-on placebo or aripiprazole would have yielded different results with regard to changes in psychopathology. The clinical implications of these findings warrant further exploration. Cost and possible side-effects need careful consideration on an individual patient basis with a focus on the likely risk-benefit ratio. Such considerations also need to be weighed against other potentially effective weight reduction strategies. In this context, the possibility of dose reduction of individual agents in combination treatment is also an option worthy of further investigation. Given the importance of patient compliance in the treatment of schizophrenia, more research is also needed to clarify the role of polypharmacy so that clinicians may optimize treatment without compromising the patient's quality of life.
Conclusion
In conclusion, combining aripiprazole and clozapine results in significant benefits in terms of weight, BMI and fasting cholesterol but not symptom improvement in patients with schizophrenia suboptimally treated with clozapine monotherapy. Improvement in weight and waist circumference may reduce metabolic risk factors associated with clozapine treatment but this has to be balanced against the higher likelihood of the aripiprazole+clozapine combination to induce AEs such as nausea, anxiety and akathisia.
